Interestingly, previous reports indicated that the PPARγ ligand, pioglitazone, also decrease STAT5A/5B mRNA levels in CML LSCs and reduced their clonogenic activity and long‐term potency in vitro. This evidence concerns the gene PPARG and chronic myelogenous leukemia, BCR-ABL1 positive.